Pinnacle Bancorp Inc. Has $35,000 Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Pinnacle Bancorp Inc. raised its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 52.0% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 190 shares of the medical research company’s stock after purchasing an additional 65 shares during the period. Pinnacle Bancorp Inc.’s holdings in Charles River Laboratories International were worth $35,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Empirical Finance LLC increased its position in Charles River Laboratories International by 4.2% in the 3rd quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock worth $258,000 after buying an additional 53 shares during the period. American Trust increased its position in Charles River Laboratories International by 5.9% during the second quarter. American Trust now owns 976 shares of the medical research company’s stock worth $202,000 after acquiring an additional 54 shares during the period. OLD National Bancorp IN raised its stake in Charles River Laboratories International by 3.1% during the 3rd quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company’s stock valued at $392,000 after purchasing an additional 59 shares during the last quarter. Fiduciary Financial Group LLC boosted its holdings in Charles River Laboratories International by 3.9% in the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock valued at $310,000 after purchasing an additional 63 shares during the period. Finally, M&T Bank Corp grew its position in Charles River Laboratories International by 3.4% in the 3rd quarter. M&T Bank Corp now owns 2,001 shares of the medical research company’s stock worth $394,000 after purchasing an additional 66 shares during the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on CRL. Bank of America cut their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. UBS Group raised their price objective on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Citigroup lowered Charles River Laboratories International from a “neutral” rating to a “sell” rating and decreased their price objective for the stock from $215.00 to $175.00 in a report on Tuesday, October 1st. William Blair reaffirmed an “outperform” rating on shares of Charles River Laboratories International in a research report on Tuesday. Finally, Robert W. Baird decreased their price target on shares of Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating on the stock in a research note on Friday, September 20th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $214.00.

Charles River Laboratories International Stock Down 4.8 %

CRL opened at $165.60 on Friday. The firm has a market cap of $8.47 billion, a price-to-earnings ratio of 20.73, a PEG ratio of 6.62 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The firm’s 50-day simple moving average is $192.56 and its 200-day simple moving average is $198.95. Charles River Laboratories International, Inc. has a twelve month low of $160.85 and a twelve month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $975.99 million. During the same period in the prior year, the firm earned $2.72 earnings per share. The company’s quarterly revenue was down 1.6% compared to the same quarter last year. Equities research analysts anticipate that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

Insider Activity at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).